$545 Million is the total value of Logos Global Management LP's 32 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | OMEGA THERAPEUTICS INC | $0 | – | -12,986 | -100.0% | -0.01% | – | |
| RAIN | Exit | RAIN THERAPEUTICS INC | $0 | – | -134,194 | -100.0% | -0.09% | – |
| Exit | SOMALOGIC INC | $0 | – | -100,000 | -100.0% | -0.10% | – | |
| BMEA | Exit | BIOMEA FUSION INC | $0 | – | -200,000 | -100.0% | -0.12% | – |
| IKNA | Exit | IKENA ONCOLOGY INC | $0 | – | -178,281 | -100.0% | -0.14% | – |
| COGT | Exit | COGENT BIOSCIENCES INC | $0 | – | -150,000 | -100.0% | -0.15% | – |
| VTGN | Exit | VISTAGEN THERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -0.16% | – |
| VRNA | Exit | VERONA PHARMA PLCsponsored ads | $0 | – | -300,000 | -100.0% | -0.19% | – |
| CGEM | Exit | CULLINAN ONCOLOGY INC | $0 | – | -200,000 | -100.0% | -0.27% | – |
| VERV | Exit | VERVE THERAPEUTICS INC | $0 | – | -96,912 | -100.0% | -0.29% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -300,000 | -100.0% | -0.96% | – |
| SRRK | Exit | SCHOLAR ROCK HLDG CORP | $0 | – | -675,000 | -100.0% | -1.13% | – |
| VERA | Exit | VERA THERAPEUTICS INCcl a | $0 | – | -385,000 | -100.0% | -1.17% | – |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -1,400,000 | -100.0% | -1.23% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -2.16% | – |
| ASND | Exit | ASCENDIS PHARMA A/Ssponsored adr | $0 | – | -175,000 | -100.0% | -2.66% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -350,000 | -100.0% | -3.73% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -1,800,000 | -100.0% | -3.93% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -1,250,000 | -100.0% | -5.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.